Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer
Status:
Terminated
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of nab-PTX and trastuzumab
for ER negative and HER2 positive operable (tumor size of 3cm or less and N0) breast cancer.